Skip Navigation


European Heart Journal Advance Access originally published online on June 25, 2007
European Heart Journal 2007 28(14):1676-1677; doi:10.1093/eurheartj/ehm233
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/14/1676    most recent
ehm233v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kintscher, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kintscher, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Does adiponectin resistance exist in chronic heart failure?

Ulrich Kintscher

Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité – Universitätsmedizin Berlin, Hessische Str. 3–4, 10115 Berlin, Germany

Corresponding author: Tel: +49 304 50525276; fax: +49 304 50525901. E-mail address: ulrich.kintscher@charite.de

This editorial refers to ‘Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure’ by T. Tsutamoto et al., on page 1723

The first 10% of the full text of this article appears below.

Adiponectin is an adipocytokine, which is mainly expressed in adipose tissue and has been identified as a potent insulin-sensitzing hormone.1 Adiponectin administration lowers glucose levels and ameliorates insulin resistance in mice.1 In humans, plasma levels of adiponectin correlate inversely with visceral fat accumulation and insulin resistance.2 Prospective and longitudinal studies have demonstrated that lower adiponectin levels are closely associated with a higher incidence of type 2 diabetes mellitus.3 In addition, adiponectin exerts pronounced anti-atherogenic and anti-inflammatory actions; therefore, it is not surprising that hypoadiponectinemia has . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure
Takayoshi Tsutamoto, Toshinari Tanaka, Hiroshi Sakai, Chitose Ishikawa, Masanori Fujii, Takashi Yamamoto, and Minoru Horie
EHJ 2007 28: 1723-1730. [Abstract] [FREE Full Text]